The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer

키워드

참고문헌 (74)

1. Siegel R, "Cancer statistics, 2014", CA Cancer J Clin, 64, pp.9~29 (2014)
2. SEER cancer statistics review(CSR)1975-2010, "Howlader N", National Cancer Institute, ~ (2013)
3. Ulrich CM, "Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics", Nat Rev Cancer, 6, pp.130~140 (2006)
4. Yue W, "Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment", Cancer Prev Res, 7, pp.388~397 (2014)
5. Coogan PF, "Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel", Cancer Epidemiol Biomarkers Prev, 9, pp.119~123 (2000)
6. Anderson KE, "Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer", J Natl Cancer Inst, 94, pp.1168~1171 (2002)
7. Tan XL, "Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study", Cancer Prev Res, 4, pp.1835~1841 (2011)
8. Schernhammer ES, "A prospective study of aspirin use and the risk of pancreatic cancer in women", J Natl Cancer Inst, 96, pp.22~28 (2004)
9. Larsson SC, "Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis", Cancer Epidemiol Biomarkers Prev, 15, pp.2561~2564 (2006)
10. Capurso G, "Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories", Aliment Pharmacol Ther, 26, pp.1089~1099 (2007)
11. Cui XJ, "High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis", Pancreas, 43, pp.135~140 (2014)
12. Rothwell PM, "Effect of daily aspirin on long-term risk of death due to cancer:analysis of individual patient data from randomised trials", Lancet, 377, pp.31~41 (2011)
13. Rozengurt E, "Mitogenic signaling pathways induced by G proteincoupled receptors", J Cell Physiol, 213, pp.589~602 (2007)
14. Nakamura K, "Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells", PLoS One, 5, pp.e8824~ (2010)
15. Inoki K, "TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth", Cell, 126, pp.955~968 (2006)
16. Fryer LG, "The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways", J Biol Chem, 277, pp.25226~25232 (2002)
17. Kisfalvi K, "Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth", Cancer Res, 69, pp.6539~6545 (2009)
18. Currie CJ, "The influence of glucose-lowering therapies on cancer risk in type 2 diabetes", Diabetologia, 52, pp.1766~1777 (2009)
19. Li D, "Antidiabetic therapies affect risk of pancreatic cancer", Gastroenterology, 137, pp.482~488 (2009)
20. Lee MS, "Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals", BMC Cancer, 11, pp.20~ (2011)
21. Bodmer M, "Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis", Am J Gastroenterol, 107, pp.620~626 (2012)
22. Singh S, "Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and metaanalysis", Am J Gastroenterol, 108, pp.510~519 (2013)
23. Sadeghi N, "Metformin use is associated with better survival of diabetic patients with pancreatic cancer", Clin Cancer Res, 18, pp.2905~2912 (2012)
24. Hwang AL, "Metformin and survival in pancreatic cancer: a retrospective cohort study", Pancreas, 42, pp.1054~1059 (2013)
25. Tella SH, "DPP-4 inhibitors: focus on safety", Expert Opin Drug Saf, 14, pp.127~140 (2015)
26. Rebours V, "The natural history of hereditary pancreatitis: a national series", Gut, 58, pp.97~103 (2009)
27. Butler AE, "Response to comments on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors", Diabetes, 62, pp.2595~2604 (2013)
28. Lee YS, "Anti-diabetic actions of glucagon-like peptide-1on pancreatic beta-cells", Metabolism, 63, pp.9~19 (2014)
29. Rondas D, "Glucagon-like peptide-1 : modulator of beta-cell dysfunction and death", Diabetes Obes Metab, 15(3), pp.185~192 (2013)
30. Elashoff M, "Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies", Gastroenterology, 141, pp.150~156 (2011)
31. White WB, "Alogliptin after acute coronary syndrome in patients with type 2 diabetes", N Engl J Med, 369, pp.1327~1335 (2013)
32. Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus", N Engl J Med, 369, pp.1317~1326 (2013)
33. Monami M, "Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials", Diabetes Obes Metab, 16, pp.48~56 (2014)
34. Egan AG, "Pancreatic safety of incretin-based drugs: FDA and EMA assessment", N Engl J Med, 370, pp.794~797 (2014)
35. Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 63(25 Pt B)[DOI]
36. Vallianou NG, "Statins and cancer", Anticancer Agents Med Chem, 14, pp.706~712 (2014)
37. di Magliano MP, "Roles for KRAS in pancreatic tumor development and progression", Gastroenterology, 144, pp.1220~1229 (2013)
38. Almoguera C, "Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes", Cell, 53, pp.549~554 (1988)
39. Rall CJ, "Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma", Pancreas, 12, pp.10~17 (1996)
40. Park HJ, "3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA", Circ Res, 91, pp.143~150 (2002)
41. Weis M, "Statins have biphasic effects on angiogenesis", Circulation, 105, pp.739~745 (2002)
42. Bocci G, "Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells", Br J Cancer, 93, pp.319~330 (2005)
43. Dulak J, "Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy", Curr Cancer Drug Targets, 5, pp.579~594 (2005)
44. Poynter JN, "Statins and the risk of colorectal cancer", N Engl J Med, 352, pp.2184~2192 (2005)
45. Singh S, "Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett’s esophagus: a systematic review and metaanalysis", Clin Gastroenterol Hepatol, 11, pp.620~629 (2013)
46. Shi M, "Statin use and risk of liver cancer: an update meta-analysis", BMJ Open, 4, pp.e005399~ (2014)
47. Khurana V, "Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans", Pancreas, 34, pp.260~265 (2007)
48. Bonovas S, "Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia:evidence from a meta-analysis of 12 studies", Am J Gastroenterol, 103, pp.2646~2651 (2008)
49. Carey FJ, "The differential effects of statins on the risk of developing pancreatic cancer: a casecontrol study in two centres in the United Kingdom", Dig Dis Sci, 58, pp.3308~3312 (2013)
50. Walker EJ, "Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study", Cancer, 121, pp.1287~1294 (2015)
51. Jeon CY, "The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis", PLoS One, 10, pp.e0121783~ (2015)
52. Hong JY, "Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients", Cancer Chemother Pharmacol, 73, pp.125~130 (2014)
53. Akbar S, "Are beta blockers new potential anticancer agents?", Asian Pac J Cancer Prev, 15, pp.9567~9574 (2014)
54. Al-Wadei HA, "Prevention of pancreatic cancer by the beta-blocker propranolol", Anticancer Drugs, 20, pp.477~482 (2009)
55. Palm D, "The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB", c nude mice is inhibited by beta-blockers, 2006, pp.118, 2744~2749
56. Drell TL IV, "Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells", Breast Cancer Res Treat, 80, pp.63~70 (2003)
57. Masur K, "Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers", Cancer Res, 61, pp.2866~2869 (2001)
58. Sood AK, "Stress hormone-mediated invasion of ovarian cancer cells", Clin Cancer Res, 12, pp.369~375 (2006)
59. Weddle DL, "Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas", Carcinogenesis, 22, pp.473~479 (2001)
60. Askari MD, "The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through beta-adrenergic transactivation of EGF receptors", J Cancer Res Clin Oncol, 131, pp.639~648 (2005)
61. Shah SM, "Does beta-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study", Br J Clin Pharmacol, 72, pp.157~161 (2011)
62. Springate DA, "Can analyses of electronic patient records be independently and externally validated? Study 2: the effect of betaadrenoceptor blocker therapy on cancer survival: a retrospective cohort study", BMJ Open, 5, pp.e007299~ (2015)
63. Udell JA, "Effect of the women’s health initiative on osteoporosis therapy and expenditure in Medicaid", J Bone Miner Res, 21, pp.765~771 (2006)
64. Watson J, "Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005", Eur J Clin Pharmacol, 63, pp.843~849 (2007)
65. Diel IJ, "Reduction in new metastases in breast cancer with adjuvant clodronate treatment", N Engl J Med, 339, pp.357~363 (1998)
66. "Breast Cancer Res", 2006, R13~
67. Gnant M, "Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12bone-mineral density substudy", Lancet Oncol, 9, pp.840~849 (2008)
68. Tassone P, "Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro", Br J Cancer, 88, pp.1971~1978 (2003)
69. Takiguchi S, "The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model", Oncol Rep, 28, pp.111~116 (2012)
70. Hiroshima Y, "The tumor-educatedmacrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid", PLoS One, 9, pp.e103382~ (2014)
71. Märten A, "Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma", delta T cells, 2007, pp.30, 370~377
72. Cardwell CR, "Exposure to oral bisphosphonates and risk of cancer", Int J Cancer, 131, pp.E717~E725 (2012)
73. Vinogradova Y, "Exposure to bisphosphonates and risk of common non-gastrointestinal cancers:series of nested case-control studies using two primary-care databases", Br J Cancer, 109, pp.795~806 (2013)
74. Zhao M, "Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer", Cancer Sci, 103, pp.58~66 (2012)

관련 논문AI추천